Improved neovascularization and wound repair by targeting human basic fibroblast growth factor (bFGF) to fibrin

Journal of Molecular Medicine

Volumn 86, Issue 10, 2008, Pages 1127-1138

  Zhao, Wenxue ^a,b   Han, Qianqian ^a,b   Lin, Hang ^a,b   Gao, Yuan ^a,b   Sun, Wenjie ^a,b   Zhao, Yannan ^a,b   Wang, Bin ^a,b   Chen, Bing ^a   Xiao, Zhifeng ^a   Dai, Jianwu ^a  

^a INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Fibrin; Growth factor; Kringle; Neovascularization; Plasma; Wound healing

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FIBRIN; KRINGLE 1 BASIC FIBROBLAST GROWTH FACTOR FUSION PROTEIN; KRINGLE 1 PROTEIN; PLASMINOGEN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BLOOD CLOT; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; EXPRESSION VECTOR; FIBRIN CLOT; FIBROBLAST; HUMAN; HUMAN CELL; MALE; NONHUMAN; RAT; SKIN FLAP; TISSUE REGENERATION; WOUND; WOUND HEALING;

ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRIN; FIBROBLAST GROWTH FACTOR 2; HUMANS; KRINGLES; MALE; MICROSCOPY, ELECTRON, SCANNING; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; WOUND HEALING;

EID: 52549122771     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-008-0372-9     Document Type: Article

References (30)

1. C Rinsch 2001 Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia Gene Ther 8 523 533
2. RJ Aviles BH Annex RJ Lederman 2003 Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2) Br J Pharmacol 140 637 646
3. AJ Singer RA Clark 1999 Cutaneous wound healing N Engl J Med 341 738 746
4. SH Lee PL Wolf R Escudero R Deutsch SW Jamieson PA Thistlethwaite 2000 Early expression of angiogenesis factors in acute myocardial ischemia and infarction N Engl J Med 342 626 633
5. K Hirose 2006 Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia Circ J 70 1190 1194
6. H Lin B Chen W Sun W Zhao Y Zhao J Dai 2006 The effect of collagen-targeting platelet-derived growth factor on cellularization and vascularization of collagen scaffolds Biomaterials 27 5708 5714
7. C Sawyers 2004 Targeted cancer therapy Nature 432 294 297
8. R Nahta FJ Esteva 2003 HER-2-targeted therapy: lessons learned and future directions Clin Cancer Res 9 5078 5084
9. SR Riddell 2004 Finding a place for tumor-specific T cells in targeted cancer therapy J Exp Med 200 1533 1537
10. LS Rosen 2005 VEGF-targeted therapy: therapeutic potential and recent advances Oncologist 10 382 391
11. P Martin 1997 Wound healing-aiming for perfect skin regeneration Science 276 75 81
12. SC Wu FJ Castellino SL Wong 2003 A fast-acting, modular-structured staphylokinase fusion with Kringle-1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy J Biol Chem 278 18199 18206
13. EA Ryan LF Mockros JW Weisel L Lorand 1999 Structural origins of fibrin clot rheology Biophys J 77 2813 2826
14. TE Petersen MR Martzen A Ichinose EW Davie 1990 Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system J Biol Chem 265 6104 6111
15. SM Hochschwender RA Laursen 1981 The lysine binding sites of human plasminogen. Evidence for a critical tryptophan in the binding site of kringle 4 J Biol Chem 256 11172 11176
16. Z Vali L Patthy 1984 The fibrin-binding site of human plasminogen. Arginines 32 and 34 are essential for fibrin affinity of the kringle 1 domain J Biol Chem 259 13690 13694
17. W Zhao B Chen X Li H Lin W Sun Y Zhao B Wang Y Zhao Q Han J Dai 2007 Vascularization and cellularization of collagen scaffolds incorporated with two different collagen-targeting human basic fibroblast growth factors J Biomed Mater Res A 82 3 630 636
18. SC Wu 2002 Functional production and characterization of a fibrin-specific single-chain antibody fragment from Bacillus subtilis: effects of molecular chaperones and a wall-bound protease on antibody fragment production Appl Environ Microbiol 68 3261 3269
19. YR Kuo FS Wang SF Jeng HC Huang FC Wei KD Yang 2004 Nitrosoglutathione modulation of platelet activation and nitric oxide synthase expression in promotion of flap survival after ischemia/reperfusion injury J Surg Res 119 92 99
20. Y Harder M Amon D Erni MD Menger 2004 Evolution of ischemic tissue injury in a random pattern flap: a new mouse model using intravital microscopy J Surg Res 121 197 205
21. I Ono 2002 The effects of basic fibroblast growth factor (bFGF) on the breaking strength of acute incisional wounds J Dermatol Sci 29 104 113
22. D Eyrich 2007 Long-term stable fibrin gels for cartilage engineering Biomaterials 28 55 65
23. A Sahni T Odrljin CW Francis 1998 Binding of basic fibroblast growth factor to fibrinogen and fibrin J Biol Chem 273 7554 7559
24. P Carmeliet 2000 VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nature Medicine 6 1102 1103
25. R Giavazzi 2003 Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis Am J Pathol 162 1913 1926
26. S Liekens J Neyts E De Clercq E Verbeken D Ribatti M Presta 2001 Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir Cancer Res 61 5057 5064
27. C Garrett 2005 Targeted therapy: the fast pace of progress Cancer Control 12 71 72
28. Y Cao 1996 Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells J Biol Chem 271 29461 29467
29. RR Hantgan WG Jerome MJ Hursting 1998 No effect of clot age or thrombolysis on argatroban's inhibition of thrombin Blood 92 2064 2074
30. I Masaki 2002 Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2 Circ Res 90 966 973